Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00058604
Other study ID # H9454
Secondary ID Euclid
Status Completed
Phase Phase 1
First received
Last updated
Start date January 2001
Est. completion date December 2008

Study information

Verified date January 2020
Source Baylor College of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients who may have been infected with EBV (Epstein-Barr Virus) before or after the time of their transplant have a higher risk of developing Lymphoproliferative Disease (LPD) or may already have a form of this disease.

This research study uses Epstein Barr virus (EBV) specific cytotoxic T lymphocytes (CTLs). These cells have been trained to attack and kill (cytotoxic) EB virus infected cells.

We make these cells from the patients blood by first growing an EBV infected B cell line by infecting the blood with an EBV virus called B-95. We then treat these EBV infected B cells with radiation so they cannot grow and use them to stimulate T cells. This stimulation will train the T cells to kill EBV infected cells. We will then test the T cells to make sure they kill the EBV infected cells.

The purpose of this study is to find the largest safe dose of EBV specific CTLs, to learn what the side effects are, and to see whether this therapy might help prevent or cure EBV related cancers in solid organ transplant patients


Description:

Participation in this study will be for one year. Patients will receive this treatment either while in hospital or in the outpatient clinic. Each patient will be entered into one of three different dosing schedules being evaluated. Three to six patients will be evaluated on each dosing schedule. Escalation will continue until unacceptable side effects are seen.

First, patients will be given Tylenol (for any aches/pains) and Benadryl (for any minor allergic reactions such as itching/rash). This is called premedication. Next, the T cells will be injected into the patients' vein (intravenously) over approximately 10 minutes. Patients will be closely watched during this time to make sure they do not experience any bad effects such as an allergic reaction. If the patient does not respond to the T cells or if during follow-up examinations evidence of relapse is shown, the patient may receive another (higher) dose of T cells approximately six weeks after their first injection. Patients may decide NOT to continue to receive this therapy (receive further injections), however, the follow-up period will still be for one year.

Each patient will be seen every two weeks in the clinic or contacted every two weeks by the research nurse or other member of the research team, for six weeks after the injection(s). They will then be seen or contacted monthly for 3 months and then once every three months for one year and again if relapse occurs or is suspected.

To learn more about the way the T cells are working and how long they last in the body, 40 mls (8 teaspoonfuls) of blood will be taken once before the injection of T-cells, every two weeks for 6 weeks after the injection, monthly for 3 months and then every 3 months for 1 year. This amount of blood will be less for small patients. We will also take another blood sample from the patient if relapse is suspected. Each patient will need to have a physical examination by their physician to check on their progress.

Additionally, before the injection of T-cells, once every two weeks after the injection for 6 weeks and once every month for 3 months and then once every 3 months for one year and again if relapse occurs or is suspected we will obtain a blood sample from the patient to evaluate for transplant rejection. The amount of blood that we will take will be 3-5 mls (1/2 to 1 teaspoon). If the patient has received a heart transplant they will also be asked to have other tests such as an ultrasound or tomography (similar to an x-ray) done to help with this evaluation.


Other known NCT identifiers
  • NCT00607698

Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender All
Age group N/A to 70 Years
Eligibility Inclusion Criteria:

- Patients falling into one of the following categories:

- Organ transplant recipients at high risk of developing LPD:

- EBV seronegative recipients

- Organ transplant recipients receiving OKT3 for immunosuppression

- Organ transplant recipients with evidence of LPD

- Organ transplant recipients with EBV DNA level >1,000 copies

- Age <70 yrs old

- Signed informed consent obtained from patient/guardian

- CTLs available

- Performance status; ECOG £ 2

- Creatinine < 3X normal

- Bilirubin < 5X normal

- AST < 5X normal

- Has not received any other investigational cellular therapies within the past 30 days.

Exclusion criteria:

- Patients with a severe intercurrent infection

- Patients with life expectancy of less than 6 weeks

- Patients receiving supplemental oxygen.

Study Design


Intervention

Biological:
Intravenous injection of EBV specific CTLs
Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course

Locations

Country Name City State
United States Texas Children's Hospital Houston Texas
United States The Methodist Hospital Houston Texas

Sponsors (3)

Lead Sponsor Collaborator
Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Generate autologous, EBV-specific, cytotoxic T cell lines (CTLs) from individuals receiving or having received a solid organ transplant (SOT). pre-treatment
Primary Administer autologous, EBV-specific CTLs to patients, to determine the safety of intravenous injections in these individuals 1 year
Primary Evaluate the antiviral and immunological efficacy of the infused CTLs 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03663933 - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Phase 2
Recruiting NCT04339777 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Phase 2
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Enrolling by invitation NCT01728402 - Pathogenesis of Hematologic Malignancies
Completed NCT00068146 - Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Completed NCT03744676 - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Phase 2
Recruiting NCT02579967 - Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies Phase 2
Recruiting NCT05803616 - Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders
Recruiting NCT02505789 - Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients N/A
Withdrawn NCT00968461 - Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders Phase 1
Recruiting NCT01186224 - Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) N/A
Terminated NCT00992732 - Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders Phase 2
Completed NCT00063648 - Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant Phase 1
Terminated NCT03601819 - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Phase 1
Active, not recruiting NCT04309084 - Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma Phase 1
Recruiting NCT04858256 - Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms Phase 2
Completed NCT03397706 - Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies Phase 1/Phase 2
Withdrawn NCT05431179 - A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Phase 3